Globus Medical (NYSE:GMED) Announces Quarterly Earnings Results

Globus Medical (NYSE:GMED) announced its earnings results on Thursday. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24, FiscalAI reports. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. The company had revenue of $789.61 million during the quarter, compared to the consensus estimate of $782.88 million. During the same period last year, the firm earned $0.86 earnings per share. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. Globus Medical updated its FY 2026 guidance to 4.950-5.050 EPS.

Here are the key takeaways from Globus Medical’s conference call:

• Positive Sentiment: Q2 revenue rose 5.9% to $789.6 million, while base-business revenue excluding Nevro increased 9%; adjusted EPS jumped 56% to a record $1.34.
• Positive Sentiment: U.S. spine grew 7%, international spine rose 14% as reported, and trauma increased 31%, supported by new products, competitive sales-force recruiting, improved inventory availability, and continued market-share gains.
• Positive Sentiment: Adjusted gross margin expanded 200 basis points to 69.4% and adjusted EBITDA margin reached 35.4%; management raised 2026 non-GAAP EPS guidance to $4.95-$5.05 while maintaining revenue guidance of $3.18-$3.22 billion.
• Negative Sentiment: Nevro sales declined 14.3% year over year and fell sequentially, while enabling-technology revenue dropped 25.8% as the company shifts toward leasing and other flexible capital-acquisition models. Management expects Nevro trial volumes to recover by late Q4, but identified both businesses as risks to second-half revenue.
• Positive Sentiment: Globus repurchased $136.1 million of shares in Q2 and has $253.9 million remaining under its authorization; it also expects to launch patient-specific SCRIPT lumbar spacers and rods in Q3, adding to a pipeline of more than 60 development projects.

Globus Medical Price Performance

NYSE:GMED traded up $1.12 during midday trading on Friday, hitting $82.20. The company’s stock had a trading volume of 3,299,652 shares, compared to its average volume of 1,551,427. Globus Medical has a fifty-two week low of $54.15 and a fifty-two week high of $101.40. The firm has a market cap of $11.16 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.67 and a beta of 0.95. The firm’s 50 day moving average is $79.33 and its 200-day moving average is $85.23.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GMED. Zacks Research cut Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. BMO Capital Markets started coverage on shares of Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective on the stock. Stifel Nicolaus cut their price objective on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a report on Wednesday, July 8th. Piper Sandler decreased their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Finally, UBS Group assumed coverage on shares of Globus Medical in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $101.77.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. The trade was a 4.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. boosted its holdings in Globus Medical by 1,235.2% during the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock worth $339,322,000 after buying an additional 3,595,339 shares in the last quarter. Bank of Montreal Can increased its holdings in Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock valued at $294,519,000 after buying an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. increased its holdings in Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock valued at $117,700,000 after buying an additional 1,908,795 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new position in shares of Globus Medical in the fourth quarter worth about $90,411,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Globus Medical by 72.1% in the third quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company’s stock worth $115,166,000 after acquiring an additional 842,547 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical News Roundup

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.